A Proof-of-mechanism Study of Multiple, Oral Doses of Fevipiprant (QAW039) in COPD Patients With Eosinophilia
Status:
Terminated
Trial end date:
2020-01-16
Target enrollment:
Participant gender:
Summary
This was an exploratory, randomized, subject- and investigator-blind, placebo-controlled,
parallel group, proof-of-mechanism study of multiple oral doses of fevipiprant (QAW039) in
chronic obstructive pulmonary disease (COPD) patients with eosinophilia.